



Astal Laboratories Limited
(Formerly known as Macro International Limited)

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Date: 27-07-2024

Sub: Submission of Unaudited Financial Results for the quarter ended 30th June, 2024 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref.: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 27th July, 2024 have considered and approved, the Unaudited Financial Results of the company for the quarter ended 30th June, 2024 along with the limited review report of the auditors thereon.


A copy of the results along with the limited review report of auditors is enclosed herewith.

The said meeting commenced at 05:00 P.M. and concluded at 05:30 P.M.

Kindly acknowledge the receipt.

Thanking You,
Yours Faithfully,

For Astal Laboratories Limited

Mahendra Kumar


Mahendra Kumar
(Company Secretary & Compliance Officer)
Membership No.: A71224


Limited Review Report

To,
Board of Directors
Astal Laboratories Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Astal Laboratories Limited** for the quarter ended on 30th June, 2024, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").


This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S


(S.S.Prakash)

Partner
Membership No.202710



UDIN : 24202710BKELYX8329

Place: Hyderabad
Date: 27th July 2024



Astal Laboratories Limited
(Formerly known as Macro International Limited)

Statement of Unaudited Financial Results for the Quarter ended on 30th June 2024

(Rs. In Lakhs except Earnings per share)					
S. No	Particulars	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year Ended
		30-06-2024	31-03-2024	30-06-2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue				
	a) From operations	1,314.57	1225.21	135.86	2364.77
	b) Other Income (Refer to Note No.3)	3.42	0.04	1.20	1.34
	Total Revenue	1,317.99	1225.25	137.06	2366.11
2	Expenses				
	(a) Cost of Material Consumed	1,159.12	1180.98	-	2239.64
	(b) Purchases of stock-in-trade	-	-	133.51	
	(c) Change in inventories of finished goods.	(166.20)	(105.76)	-	(105.76)
	work-in-progress and stock-in-trade	-	-	-	-
	(d) Employees Benefits expenses	40.76	39.00	1.66	46.57
	(e) Finance Cost	6.29	-	-	1.08
	(f) Depreciation amortization expenses	1.28	2.00	0.20	2.95
	(g) Other Expenses	42.90	53.21	0.41	72.97
	Total Expenses	1084.15	1169.43	135.78	2257.45
3	Profit from ordinary activities before exceptional Items (1 - 2)	233.84	55.83	1.28	108.66
4	Exceptional Items - Income/ (Expenses)	-	-	-	-
5	Profit from ordinary activities before tax (3 - 4)	233.84	55.82	1.28	108.66
6	Tax Expenses	-	-	-	-
	(a) Current Tax	62.29	-	-	29.37
	(b) Deferred Tax	2.64	-	-	0.82
7	Profit/(Loss) for the period (5 - 6)	168.91	55.82	1.28	78.47
8.	A (i) Items that will not be reclassified to profit or loss (net of tax) (ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-

Regd. Office: 24/147, Ground Floor, Plaza Kalpana, Birhana Road, Kanpur -208001, India
Corporate Office: # 304, 3rd Floor, Babukhan Estate, Basheer Bagh, Hyderabad 500001, TS, India
Mob. No: 6302730973, CIN: L74120UP1993PLC015605, SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Website: <https://miel.co.in/>





Astal Laboratories Limited
(Formerly known as Macro International Limited)

	B (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-
9	Total Comprehensive Income, net of tax (7 + 8)	168.91	55.82	1.28	78.47
10	Paid up equity share capital (Face Value of Rs.10/- each)	984.56	984.56	398.96	984.56
11	Earnings per share (of Rs.10/-each) not annualized	-	-	-	-
	(a) Basic	1.716	1.105	0.030	1.554
	(b) Diluted	1.716	1.105	0.030	1.554

See accompanying notes to financial results

NOTES:

1	The above Unaudited Financial Results of the company for the quarter ended June 30 th 2024 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on July 27 th , 2024.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.

For ASTAL LABORATORIES LIMITED

SUDHEER KARNA KANKANALA
(Whole time Director)

DIN: 07591466

Date: 27/07/2024

Place: Hyderabad

